A7 Cont

27. (New) The method of Claim 23 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

28. (New) The method of Claim 24 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.

29. (New) The method of Claim 28 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

30. (New) The method of Claim 24 wherein the mammal is at risk for developing a tumor.

31. (New) The method of Claim 23 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, am emulsion, a powder, an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

32. (New) The method of Claim 24 wherein the mammal is a human.

33. (New) The method of Claim 32 wherein the human has a primary tumor.

34. (New) The method of Claim 33 wherein the primary tumor is selected from the group consisting of Kaposi's sarcoma, hemangiomas, solid tumors, blood-born tumors, rhabdomyosarcoma, retinoblastoma, Ewings's sarcoma, neuroblastoma, osteosarcoma, leukemia, neurofibroma, pyogenic granulosum, and breast cancer.

35. (New) The method of Claim 33 wherein the thalidomide is administered orally, sublingually, buccally, rectally, vaginally, transdermally, topically, basally, or parenterally.

AP Cont

36. (New) The method of Claim 33 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

37. (New) The method of Claim 36 wherein the thalidomide is administered in an amount between approximately 0.5 and approximately 50 mg/kg/day.

38. (New) The method of Claim 37 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

39. (New) The method of Claim 33 wherein the thalidomide is administered in the form of a tablet or capsule.

40. (New) The method of Claim 33 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, am emulsion, a powder, an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

Sub B2

41. (New) A method for inhibiting metastasis of tumors in a human or animal having at least one primary tumor comprising administering an angiogenesis inhibiting amount of thalidomide to said human or animal.

42. (New) The method of Claim 41 wherein the primary tumor is selected from the group consisting of Kaposi's sarcoma, hemangiomas, solid tumors, blood borne tumors, rhabdomyosarcoma, retinoblastoma, Ewings's sarcoma, neuroblastoma, osteosarcoma, leukemia, neurofibroma, pyogenic granulosum, and breast cancer.

43. (New) The method of Claim 41 wherein the thalidomide is administered orally, sublingually, buccally, rectally, vaginally, transdermally, topically, basally, or parenterally.

A2 Cont

44. (New) The method of Claim 41 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

45. (New) The method of Claim 44 wherein the thalidomide is administered in an amount between approximately 0.5 and approximately 50 mg/kg/day.

46. (New) The method of Claim 45 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

47. (New) The method of Claim 41 wherein the thalidomide is administered in the form of a tablet or capsule.

48. (New) The method of Claim 41 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, am emulsion, a powder, an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

49. (New) A method for reducing the recurrence of a tumor by inhibiting angiogenesis in a human or animal comprising administering an angiogenesis inhibiting amount of thalidomide to said human or animal.

50. (New) The method of Claim 49 wherein the human or animal is undergoing cancer therapy.

51. (New) The method of Claim 49 wherein the tumor is no longer present in said human or animal.

52. (New) The method of Claim 49 wherein the thalidomide is administered orally, sublingually, buccally, rectally, vaginally, transdermally, topically, basally, or parenterally.

A2 Cont

53. (New) The method of Claim 49 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

54. (New) The method of Claim 53 wherein the thalidomide is administered in an amount between approximately 0.5 and approximately 50 mg/kg/day.

55. (New) The method of Claim 54 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

56. (New) The method of Claim 49 wherein the thalidomide is administered in the form of a tablet or capsule.

57. (New) The method of Claim 49 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, am emulsion, a powder, an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.